Jinny Tavee, MD
Neurology · Denver, CONPI 1437123940
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $47,348 of the $58,361 with a category attached, or 81.1%. CSL Behring accounts for 71.9% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $24,934 and has fallen 79.5% since, to $5,116 in 2025. Among neurology clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 45 payments — averaging $1296.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$42K
- AstraZeneca$8K
- Argenx US, Inc.$7K
- Janssen Scientific Affairs, LLC$1K
- Merz Pharmaceuticals, LLC$85
- Teva Pharmaceuticals USA, Inc.$35
- plus $22 from 1 others
Across 23 payments — averaging $7260.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$167K
What the payments were for
- Consulting fees$47,34881%
- Speaking & faculty fees$7,71013%
- Travel & lodging$2,3284%
- Food & beverage$8571%
- Education$1200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 22 | $41,974 |
| AstraZeneca | 9 | $7,910 |
| Argenx US, Inc. | 10 | $7,245 |
| Janssen Scientific Affairs, LLC | 1 | $1,090 |
| Merz Pharmaceuticals, LLC | 1 | $85 |
| Teva Pharmaceuticals USA, Inc. | 1 | $35 |
| Lundbeck LLC | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$58,361 in reported general payments places this provider in the 90th percentile of 334 neurology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FirdapseAmifampridine Phosphate | 11 | $468,120 |
| Radicava OrsEdaravone | 13 | $184,184 |
| Droxidopa | 14 | $3,113 |
| Gabapentin | 102 | $2,577 |
| Pyridostigmine Bromide | 24 | $794 |
| Pregabalin | 21 | $707 |
| Duloxetine Hcl | 30 | $658 |
| Nortriptyline Hcl | 21 | $325 |
| Baclofen | 26 | $300 |
| Donepezil Hcl | 18 | $221 |
| Topiramate | 26 | $191 |
| Omeprazole | 16 | $102 |
| Prednisone | 12 | $92 |
| Meloxicam | 14 | $58 |
Paid to pharmacies, not to this prescriber.
Other neurology in Denver
- Justin MoonDenver$1.4M
- Michael AmentDenver$457K
- Adam WolffDenver$364K
- Shankar PerumalDenver$61K
- Alexander FeldmanDenver$28K
- James McNuttDenver$27K
- Jared YarnellDenver$27K
- Ralph RoundDenver$26K
- Jonathan DatarDenver$25K
- Tamara MillerFort Collins$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.